12,372 trials
Non-Small Cell Lung Cancer (NSCLC)
Primary: Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR) — 16.69; 15.64 months — p=0.6460
Treatment of Bleeding · Prophylaxis of Bleeding · Hemophilia A
Primary: Adverse Events of Special Interest (AESI) Hypersensitivity and Loss of Efficacy Associated With the First 4 Exposure Days (EDs) Leading to Discontinuation — 1 Participants
Prostate Cancer
Primary: Percentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the Study — 95.0 percentage of participants
Dry Eye Disease
Primary: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer…
Dry Eye Disease
Primary: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer…
Mantle-Cell Lymphoma
Primary: Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in) — 1; 0 Participants
Carcinoma, Squamous Cell
Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243
Chronic Migraine · Episodic Migraine
Primary: Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs) — 88.4; 90.3; 4.5; 0.0 percentage…
Pruritus
Primary: Part A: Mean Change From Baseline in Monthly Itch Scores Over 24 Weeks Using Numerical Rating Scale (NRS) — -2.86; -2.15 Scores on a scale — p=0.001
Overuse Injury · Body Mass Index in Athletes
Primary: Efficacy of Hyaluronic Acid With Sorbitol (SYNOLIS VA) in Overuse Knee Syndrome Assessed With the Knee Injury and Osteoarthritis Outcome Score (KOOS) — 68; 78; 84; 88…
Heavy Menstrual Bleeding · Uterine Fibroids
Primary: Number of Participants With Adverse Events (AEs) — 203; 83; 124; 59 Participants
AIDS
Primary: Proportion of Patients Free of Therapeutic Failure — 47; 20; 0; 2 Participants
HIV Infection · Hepatitis B
Primary: Percentage of Participants With Primary Seroprotection Response — 93.1; 99.4; 80.6; 100 percentage of participants
Covid19
Primary: Time to Sustained Recovery in Days — 9; 10 days
Human Papillomavirus-Related Cervical Carcinoma
Primary: Number Seropositive for HPV16 at 36 Months — 538; 366 Participants